Address

Atlas Venture
25 First Street
Suite 303
Cambridge, MA 02141
United States

Open map


Recent investment activity

KANDO id: 24121

Corporate information

Founders
Registration country

Company type

Early-stage venture capital firm that creates and invests in biotechnology startup companies in the US.

Funding rounds

Top investment portfolio themes

Actual initial investment stage
N/A (53)
Series A (28)
Seed (9)
Other (1)

Investment activity status
Active investor

Selected investments

Displaying 26 - 50 of 117
Profile Country Date Sort ascending Funding
EnglishCentral Inc A web-based English language learning startup company. Seed Initial investment 1,380,000 (USD 1,380,000)
Advanced Electron Beams Inc (AEB) Provider of electron beam energy technology products and solutions worldwide. Series C Initial investment 14,200,000 (USD 14,200,000)
Keas Inc Provider of online care plans for individuals. Series A Initial investment 10,000,000 (USD 10,000,000)
Lilliputian Systems Inc Developer of fuel cell system and chips for consumer electronics devices. N/A Initial investment 28,000,000 (USD 28,000,000)
DataXu Inc Provider of the leading real-time media management platform for digital advertising campaigns across online, mobile and video channels. Series A Initial investment 7,800,000 (USD 7,800,000)
ProtAffin Biotechnologie AG A biotechnology company developing a novel class of biopharmaceuticals based on glycan-binding decoy proteins. Series B Initial investment 14,100,000
CloudSwitch Inc Provider of innovative software appliance that empowers an enterprise. Series A Initial investment 7,400,000 (USD 7,400,000)
Zoopla Ltd UK online real estate listings site. Series B Initial investment 5,440,000 (USD 5,440,000)
Inspirational Stores SA A French company of e-commerce which has a very strong growth, exploiting numerous prestigious brands in France and internationally. Series B Initial investment 10,000,000 (USD 10,000,000)
MiaSole Inc (Miasolé Inc) Series D Initial investment
NTRglobal A Spanish-based developer of software as a service solutions, offers remote support, remote access and remote systems management solutions. Series C Initial investment 34,000,000 (USD 34,000,000)
Miragen Therapeutics Inc Ddeveloper of cardiovascular and muscle disease therapeutics based on microRNA biology. Series A Initial investment 8,000,000 (USD 8,000,000)
ShoZu Developer of an application which allows you to upload to social sites like Flickr. Series C Follow-on investment
Vitae Pharmaceuticals Inc Drug discovery company developing optimized drugs using proprietary computational drug design platform. Other Initial investment 15,000,000 (USD 15,000,000)
OwnerIQ Inc Developer of a real-time media buying platform. Series A Initial investment 2,000,000 (USD 2,000,000)
Icera Inc A fabless semiconductor company, developed a high performance soft modem technology for mobile broadband phone and data devices. Series D Initial investment 40,000,000 (USD 40,000,000)
Icera Semiconductor Inc Series D Initial investment
VideoIQ Inc Intelligent video surveillance company. Series A Initial investment 8,000,000 (USD 8,000,000)
Marathon Technologies Corp Provider of fault-tolerant and disaster recovery software solutions for physical and virtual servers. Series B Initial investment 12,000,000 (USD 12,000,000)
Stromedix Inc A biotechnology company committed to developing novel drugs to treat fibrotic organ failure. Series A Initial investment 1,000,000 (USD 1,000,000)
Avila Therapeutics Inc A biotechnology company, pioneering a method to discover and develop new small-molecule medicines that achieve 'protein silencing'. Series A Initial investment 21,000,000 (USD 21,000,000)
f-star Biotechnologische Forschungs- und Entwicklungsges mbH (f-star), (f-star Biotech) A next generation antibody company developing improved therapeutic antibodies and antibody fragments based on its unique Modular Antibody Technology. Seed Initial investment 1,950,000 (USD 1,950,000)
JenaValve Technology GmbH A medical device company focused on developing transcatheter-delivered aortic valve systems to treat patients suffering from aortic valve disease. Series A Initial investment
Pioneers of the Inevitable Inc (POTI) A group of designers and developers who believe in the promise of an open customizable media player. Seed Initial investment 8,000,000 (USD 8,000,000)
Trade sale
Profile Country Date Sort ascending Funding
Ubiquisys Ltd Developer of convergence solutions that enable mobile operators to speed up and fully benefit from fixed mobile substitution Series B Follow-on investment Exited Trade sale

Current team

Past employees

Selected Products / Customers

Financials